Cargando…

In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine

Significant concerns have been raised owing to the rapid global spread of infection and disease caused by the mosquito-borne Zika virus (ZIKV). Recent studies suggest that ZIKV can also be transmitted sexually, further increasing the exposure risk for this virus. Associated with this spread is a dra...

Descripción completa

Detalles Bibliográficos
Autores principales: Muthumani, Karuppiah, Griffin, Bryan D, Agarwal, Sangya, Kudchodkar, Sagar B, Reuschel, Emma L, Choi, Hyeree, Kraynyak, Kimberly A, Duperret, Elizabeth K, Keaton, Amelia Anne, Chung, Christopher, Kim, Yinho K, Booth, Stephanie A, Racine, Trina, Yan, Jian, Morrow, Matthew P, Jiang, Jingjing, Lee, Brian, Ramos, Stephanie, Broderick, Kate E, Reed, Charles C, Khan, Amir S, Humeau, Laurent, Ugen, Kenneth E, Park, Young K, Maslow, Joel N, Sardesai, Niranjan Y, Joseph Kim, J, Kobinger, Gary P, Weiner, David B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707885/
https://www.ncbi.nlm.nih.gov/pubmed/29263859
http://dx.doi.org/10.1038/npjvaccines.2016.21
_version_ 1783282532982194176
author Muthumani, Karuppiah
Griffin, Bryan D
Agarwal, Sangya
Kudchodkar, Sagar B
Reuschel, Emma L
Choi, Hyeree
Kraynyak, Kimberly A
Duperret, Elizabeth K
Keaton, Amelia Anne
Chung, Christopher
Kim, Yinho K
Booth, Stephanie A
Racine, Trina
Yan, Jian
Morrow, Matthew P
Jiang, Jingjing
Lee, Brian
Ramos, Stephanie
Broderick, Kate E
Reed, Charles C
Khan, Amir S
Humeau, Laurent
Ugen, Kenneth E
Park, Young K
Maslow, Joel N
Sardesai, Niranjan Y
Joseph Kim, J
Kobinger, Gary P
Weiner, David B
author_facet Muthumani, Karuppiah
Griffin, Bryan D
Agarwal, Sangya
Kudchodkar, Sagar B
Reuschel, Emma L
Choi, Hyeree
Kraynyak, Kimberly A
Duperret, Elizabeth K
Keaton, Amelia Anne
Chung, Christopher
Kim, Yinho K
Booth, Stephanie A
Racine, Trina
Yan, Jian
Morrow, Matthew P
Jiang, Jingjing
Lee, Brian
Ramos, Stephanie
Broderick, Kate E
Reed, Charles C
Khan, Amir S
Humeau, Laurent
Ugen, Kenneth E
Park, Young K
Maslow, Joel N
Sardesai, Niranjan Y
Joseph Kim, J
Kobinger, Gary P
Weiner, David B
author_sort Muthumani, Karuppiah
collection PubMed
description Significant concerns have been raised owing to the rapid global spread of infection and disease caused by the mosquito-borne Zika virus (ZIKV). Recent studies suggest that ZIKV can also be transmitted sexually, further increasing the exposure risk for this virus. Associated with this spread is a dramatic increase in cases of microcephaly and additional congenital abnormalities in infants of ZIKV-infected mothers, as well as a rise in the occurrence of Guillain Barre’ syndrome in infected adults. Importantly, there are no licensed therapies or vaccines against ZIKV infection. In this study, we generate and evaluate the in vivo efficacy of a novel, synthetic, DNA vaccine targeting the pre-membrane+envelope proteins (prME) of ZIKV. Following initial in vitro development and evaluation studies of the plasmid construct, mice and non-human primates were immunised with this prME DNA-based immunogen through electroporation-mediated enhanced DNA delivery. Vaccinated animals were found to generate antigen-specific cellular and humoral immunity and neutralisation activity. In mice lacking receptors for interferon (IFN)-α/β (designated IFNAR(−/−)) immunisation with this DNA vaccine induced, following in vivo viral challenge, 100% protection against infection-associated weight loss or death in addition to preventing viral pathology in brain tissue. In addition, passive transfer of non-human primate anti-ZIKV immune serum protected IFNAR(−/−) mice against subsequent viral challenge. This study in NHP and in a pathogenic mouse model supports the importance of immune responses targeting prME in ZIKV infection and suggests that additional research on this vaccine approach may have relevance for ZIKV control and disease prevention in humans.
format Online
Article
Text
id pubmed-5707885
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-57078852017-12-20 In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine Muthumani, Karuppiah Griffin, Bryan D Agarwal, Sangya Kudchodkar, Sagar B Reuschel, Emma L Choi, Hyeree Kraynyak, Kimberly A Duperret, Elizabeth K Keaton, Amelia Anne Chung, Christopher Kim, Yinho K Booth, Stephanie A Racine, Trina Yan, Jian Morrow, Matthew P Jiang, Jingjing Lee, Brian Ramos, Stephanie Broderick, Kate E Reed, Charles C Khan, Amir S Humeau, Laurent Ugen, Kenneth E Park, Young K Maslow, Joel N Sardesai, Niranjan Y Joseph Kim, J Kobinger, Gary P Weiner, David B NPJ Vaccines Article Significant concerns have been raised owing to the rapid global spread of infection and disease caused by the mosquito-borne Zika virus (ZIKV). Recent studies suggest that ZIKV can also be transmitted sexually, further increasing the exposure risk for this virus. Associated with this spread is a dramatic increase in cases of microcephaly and additional congenital abnormalities in infants of ZIKV-infected mothers, as well as a rise in the occurrence of Guillain Barre’ syndrome in infected adults. Importantly, there are no licensed therapies or vaccines against ZIKV infection. In this study, we generate and evaluate the in vivo efficacy of a novel, synthetic, DNA vaccine targeting the pre-membrane+envelope proteins (prME) of ZIKV. Following initial in vitro development and evaluation studies of the plasmid construct, mice and non-human primates were immunised with this prME DNA-based immunogen through electroporation-mediated enhanced DNA delivery. Vaccinated animals were found to generate antigen-specific cellular and humoral immunity and neutralisation activity. In mice lacking receptors for interferon (IFN)-α/β (designated IFNAR(−/−)) immunisation with this DNA vaccine induced, following in vivo viral challenge, 100% protection against infection-associated weight loss or death in addition to preventing viral pathology in brain tissue. In addition, passive transfer of non-human primate anti-ZIKV immune serum protected IFNAR(−/−) mice against subsequent viral challenge. This study in NHP and in a pathogenic mouse model supports the importance of immune responses targeting prME in ZIKV infection and suggests that additional research on this vaccine approach may have relevance for ZIKV control and disease prevention in humans. Nature Publishing Group 2016-11-10 /pmc/articles/PMC5707885/ /pubmed/29263859 http://dx.doi.org/10.1038/npjvaccines.2016.21 Text en Copyright © 2016 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Muthumani, Karuppiah
Griffin, Bryan D
Agarwal, Sangya
Kudchodkar, Sagar B
Reuschel, Emma L
Choi, Hyeree
Kraynyak, Kimberly A
Duperret, Elizabeth K
Keaton, Amelia Anne
Chung, Christopher
Kim, Yinho K
Booth, Stephanie A
Racine, Trina
Yan, Jian
Morrow, Matthew P
Jiang, Jingjing
Lee, Brian
Ramos, Stephanie
Broderick, Kate E
Reed, Charles C
Khan, Amir S
Humeau, Laurent
Ugen, Kenneth E
Park, Young K
Maslow, Joel N
Sardesai, Niranjan Y
Joseph Kim, J
Kobinger, Gary P
Weiner, David B
In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
title In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
title_full In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
title_fullStr In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
title_full_unstemmed In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
title_short In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
title_sort in vivo protection against zikv infection and pathogenesis through passive antibody transfer and active immunisation with a prmenv dna vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707885/
https://www.ncbi.nlm.nih.gov/pubmed/29263859
http://dx.doi.org/10.1038/npjvaccines.2016.21
work_keys_str_mv AT muthumanikaruppiah invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT griffinbryand invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT agarwalsangya invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT kudchodkarsagarb invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT reuschelemmal invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT choihyeree invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT kraynyakkimberlya invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT duperretelizabethk invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT keatonameliaanne invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT chungchristopher invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT kimyinhok invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT boothstephaniea invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT racinetrina invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT yanjian invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT morrowmatthewp invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT jiangjingjing invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT leebrian invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT ramosstephanie invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT broderickkatee invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT reedcharlesc invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT khanamirs invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT humeaulaurent invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT ugenkennethe invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT parkyoungk invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT maslowjoeln invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT sardesainiranjany invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT josephkimj invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT kobingergaryp invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine
AT weinerdavidb invivoprotectionagainstzikvinfectionandpathogenesisthroughpassiveantibodytransferandactiveimmunisationwithaprmenvdnavaccine